Read the Conversation
Conversation highlights:
- The company positions itself as a strategic partner rather than a traditional distributor, enabling access to breakthrough medical technologies through market access, reimbursement, and clinical implementation.
- IntelMed expanded across the GCC as of 2018, establishing a direct presence across Saudi Arabia, UAE, Qatar, Bahrain, and Oman, while maintaining operations in Lebanon and Egypt.
- The Middle East lacks comprehensive medical databases, requiring local partners to rely on proprietary data, local expertise, and structured market insights supported by international benchmarks.
- Clinical education and training form a core part of IntelMed’s approach, with clinically driven sales teams supporting the implementation of innovative technologies in centers of excellence.
- The company has evolved from working with startup medtech companies to partnering with multinational corporations, while maintaining its focus on enabling the adoption of high-impact healthcare innovation.
EF: Could you tell us about IntelMed's background and how the company has evolved over the past 15 years?
NH: We started IntelMed after I spent 11 years in France working in market intelligence and reimbursement. From the beginning, our objective was not only to introduce new technologies but to enable access to them at the local level.
We started with advanced heart failure therapies, particularly LVADs, where the key challenge was not just distribution but securing reimbursement. By structuring access pathways, we were able to unlock treatment for patients who previously had no access to these life-saving therapies, achieving more than 90% market adoption within two years. From there, we expanded into endovascular procedures such as EVAR and TAVR, as well as stroke care. As the environment evolved, we expanded across the GCC as of 2018, establishing a presence across Saudi Arabia, the UAE, Qatar, Bahrain, and Oman.
Today, IntelMed operates as a bridge between global innovation and regional healthcare systems, combining market access, reimbursement, and clinical implementation to ensure the successful adoption of breakthrough technologies.
EF: How has the relationship between distributors and medtech companies evolved, and how do you choose your partners?
NH: We see ourselves as strategic partners, not distributors. We choose partners based on alignment in strategy, vision, and the ability to implement innovation successfully on the ground. Even when technologies are strong, misalignment in vision often leads to failure. Our strength lies in combining on the ground execution with a deep understanding of how to position and scale innovation within complex healthcare systems.
EF: How do you assess the data infrastructure available across the Gulf markets, and what improvements are needed?
NH: One of the main challenges in the region is the lack of comprehensive healthcare databases, unlike in Europe or the US. As a result, decision making relies heavily on local expertise, proprietary data, and experience. We complement this with structured approaches such as extrapolation and benchmarking based on international markets.
This is why strong local partners are essential, understanding and interpreting data within the local context is what drives successful outcomes.
EF: Could you tell us about the clinical side of your work, particularly your role in supporting initial procedures and training physicians?
NH: Introducing breakthrough technologies requires more than technical expertise; it requires clinical integration. Our teams are structured with clinical specialists who can engage meaningfully with physicians.
We focus on centers of excellence to ensure that initial procedures are performed under optimal conditions, enabling successful adoption and strong clinical outcomes.
EF: What kind of people do you need at IntelMed, given the evolving technological landscape?
NH: We look for individuals who combine curiosity, ambition, and the ability to bridge clinical and commercial perspectives. The complexity of innovation today requires profiles that can understand both the technical and clinical dimensions of healthcare. AI and digital tools enhance efficiency and enable remote support, but they remain complementary.
Ultimately, success still depends on human expertise and strong execution on the ground.
EF: Reflecting on 15 years of IntelMed, what are the key milestones that stand out?
NH: A key milestone was our regional expansion, where we expanded across the GCC as of 2018, building a strong presence across multiple markets. Another milestone was our evolution from working with startup medtech companies to partnering with multinational organizations like J&J, Edwards, and Abbott.
Despite this evolution, we have maintained the same core focus: enabling the adoption of high-impact innovations that transform clinical practice.
EF: Is there anything else you’d like to add for our readers?
NH: We differentiate ourselves by integrating regulatory, market access, reimbursement, clinical, and commercial expertise. This integrated approach is essential to successfully introduce innovation in complex healthcare systems.
Our role is to ensure that the right technologies reach the right patients, under the right conditions, and with sustainable access.
